Galux utilizes an integrated in silico drug discovery platform, combining protein structure modeling with artificial intelligence to identify and develop novel therapeutics for incurable and rare diseases. This technology enhances the efficiency and accuracy of drug discovery, addressing the critical need for effective treatments in underserved medical areas.
Funding
Funding not disclosed
Founders
Product
Problem
The discovery of new therapeutics for incurable and rare diseases is a slow and expensive process, often hampered by inefficient screening methods and a limited understanding of protein structures. Traditional drug discovery approaches struggle to address the unique challenges posed by rare diseases, leaving many patients without effective treatment options.
Solution
Galux is developing an in silico drug discovery platform that integrates protein structure modeling with artificial intelligence to accelerate the identification and development of novel therapeutics. By combining physics, chemistry, and AI, the platform aims to enhance the efficiency and accuracy of drug discovery, particularly for incurable and rare diseases. The core technology is based on the "GALAXY" protein structure modeling platform, which has demonstrated high performance in blind experiments.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and drug development organizations focused on discovering and developing treatments for rare and incurable diseases.
Features
- Integrated in silico drug discovery platform combining physics, chemistry, and artificial intelligence.
- Protein structure modeling platform "GALAXY" for accurate protein structure prediction.
- AI-driven algorithms for identifying potential drug candidates.
- Focus on developing therapeutics for incurable and rare diseases.